Xin Lang Cai Jing·2025-10-09 01:44Core Insights - Nocera Biopharma experienced a stock price increase of 9.99%, reaching 31.37 CNY per share, with a trading volume of 113 million CNY and a turnover rate of 1.40%, resulting in a total market capitalization of 55.357 billion CNY [1] Company Overview - Nocera Biopharma, established on November 3, 2015, and listed on September 21, 2022, is based in Beijing, China. The company focuses on the research, production, and commercialization of biopharmaceuticals, particularly in oncology and autoimmune diseases, addressing unmet clinical needs [1] - The company's product pipeline includes ICP-022, ICP-B04, ICP-490, ICP-192, and ICP-723, among others. Its primary business operations are conducted in China and the United States [1] - Revenue composition is as follows: 87.67% from drug sales, 12.04% from technology licensing, and 0.15% each from testing and research services [1] Fund Holdings - According to data, one fund under ICBC Credit Suisse holds a significant position in Nocera Biopharma. The fund, ICBC Credit Suisse Zhaorui One-Year Holding Mixed A (014799), held 119,500 shares in the second quarter, accounting for 0.82% of the fund's net value, ranking as the tenth largest holding [2] - The fund has a current scale of 319 million CNY and has achieved a year-to-date return of 13.65%, ranking 5569 out of 8238 in its category. Over the past year, it has returned 17.39%, ranking 4651 out of 8082, and since inception, it has returned 16.59% [2] Fund Manager Information - The fund manager of ICBC Credit Suisse Zhaorui One-Year Holding Mixed A is Zhao Jian, who has been in the position for 3 years and 235 days. The total asset size of the fund is 17.478 billion CNY, with the best return during his tenure being 16.35% and the worst being 0.08% [3]